MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Bayer AG

Ouvert

SecteurFinance

23.065 2.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

22.415

Max

23.135

Chiffres clés

By Trading Economics

Revenu

3.9B

-328M

Ventes

1.8B

12B

P/E

Moyenne du Secteur

30.9

20.525

BPA

1.05

Rendement du dividende

0.52

Marge bénéficiaire

-2.796

Employés

90,587

EBITDA

615M

1.7B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+18.73% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.52%

4.36%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-599M

21B

Ouverture précédente

20.63

Clôture précédente

23.065

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Bayer AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 mars 2025, 09:37 UTC

Principaux Mouvements du Marché

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 mars 2025, 11:21 UTC

Résultats

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 mars 2025, 08:45 UTC

Résultats

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 mars 2025, 07:26 UTC

Résultats

Bayer Warns of Lower Earnings as Work Continues on Turnaround

14 avr. 2025, 13:00 UTC

Actualités

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7 avr. 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mars 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5 mars 2025, 13:39 UTC

Market Talk
Résultats

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 mars 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 mars 2025, 08:30 UTC

Market Talk
Résultats

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 mars 2025, 06:41 UTC

Résultats

Bayer Launches Plan to Boost Profitability at Crop Science

5 mars 2025, 06:40 UTC

Résultats

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 mars 2025, 06:39 UTC

Résultats

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 mars 2025, 06:39 UTC

Résultats

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 mars 2025, 06:36 UTC

Résultats

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 mars 2025, 06:35 UTC

Résultats

Bayer Guidance is on a Currency Adjusted Basis

5 mars 2025, 06:34 UTC

Résultats

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 mars 2025, 06:34 UTC

Résultats

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 mars 2025, 06:33 UTC

Résultats

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 mars 2025, 06:33 UTC

Résultats

Bayer Sees 2025 Sales EUR45B-EUR47B

5 mars 2025, 06:32 UTC

Résultats

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 mars 2025, 06:31 UTC

Résultats

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 mars 2025, 06:31 UTC

Résultats

Bayer 4Q Net Loss EUR335M

5 mars 2025, 06:31 UTC

Résultats

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 mars 2025, 06:31 UTC

Résultats

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 mars 2025, 06:31 UTC

Résultats

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 mars 2025, 06:31 UTC

Résultats

Bayer 4Q Sales EUR11.73B

13 janv. 2025, 21:05 UTC

Actualités

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 janv. 2025, 15:06 UTC

Acquisitions, Fusions, Rachats

Bayer Didn't Disclose Financial Details

Comparaison

Variation de prix

Bayer AG prévision

Objectif de Prix

By TipRanks

18.73% hausse

Prévisions sur 12 Mois

Moyen 26.69 EUR  18.73%

Haut 33 EUR

Bas 22 EUR

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

11 ratings

1

Achat

10

Maintien

0

Vente

Score Technique

By Trading Central

21 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.